MRK
MRNA
A cancer-shot moment
Moderna and Merck just hit a pretty wild milestone: the first positive Phase 3 readout ever for an individualized mRNA cancer therapy. That’s not just a science win — it’s the kind of data that can turn a “cool biotech idea” into a real commercial story.
Why Merck cares even if Moderna’s the headline
Sure, Moderna is getting the fireworks. But Merck owns half of this thing, and that’s the part long-term investors should keep an eye on. Under their deal, the two companies split costs and profits 50/50 worldwide, which means this isn’t some side quest for Merck — it’s one of its post-Keytruda escape hatches.
The Keytruda chess game
Merck’s big worry has been the patent cliff around Keytruda, its mega-blockbuster immunotherapy. So the company has been lining up backup plans: reformulate, buy stuff, and keep building next-gen combos that make pembrolizumab harder to replace. This cancer vaccine program fits neatly into that third bucket.
If the therapy keeps working and eventually gets to market, Merck doesn’t just get another product. It gets a way to keep patients inside its ecosystem a little longer, which is the corporate version of extending the final scene in a blockbuster because the sequel rights are too valuable to lose.
Big picture: Moderna got the stock pop, but Merck may have just taken a meaningful step toward life after Keytruda — and that could be the bigger long-game win.